Aviir Obtains $30,000,000 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    2463 Faber Place Palo Alto, CA 94303
  • Company Description
    Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology draws on years of research at Stanford University, and combines the scientific founders’ deep understanding of disease marker proteins and advanced biostatistics. Aviir is pursuing an aggressive commercialization strategy, with initial products expected to reach the market in 2008.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The proceeds will be used to fund commercialization of TruRisk(TM), Aviir’s proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories, based in Irvine, California.
  • M&A Terms
  • Venture Investor
    Merck Capital Ventures
  • Venture Investor
    Bay City Capital
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Aberdare Ventures

Trending on Xconomy